Amplexd Therapeutics, Innovating to Revolutionize the Future of Non-Invasive HPV-induced Cervical Intraepithelial Neoplasia (CIN) Treatments for the Prevention of Cervical Cancer: Developed by Women for Women
The Company has secured US$2 Million for this initiative from an Asia-based life sciences focused family office.
- The Company has secured US$2 Million for this initiative from an Asia-based life sciences focused family office.
- “The funding marks a major milestone in our R&D efforts for our two therapies after extremely promising preclinical studies were completed.
- CIN results from certain oncogenic varieties of HPV, which can transform cervical cells into invasive cancer if left untreated.
- My hope is that once approved, others can have an experience better than my own, without compromising quality of care,” Rahman added.